Michael Dombek, DPM
Foot & Ankle Surgery · Peachtree City, GANPI 1588668289
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $10,027 of the $10,626 with a category attached, or 94.4%. Fuse Medical, Inc. accounts for 94.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $3,867 and has fallen 96.1% since, to $151 in 2025.
Across 23 payments — averaging $462.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fuse Medical, Inc.$10K
- Hikma Pharmaceuticals USA$151
- Medtronic$149
- Nevro Corp.$146
- Amgen$84
- Globus Medical$33
- plus $35 from 2 others
What the payments were for
- Royalty or licence$10,02794%
- Food & beverage$5996%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fuse Medical, Inc. | 4 | $10,027 |
| Hikma Pharmaceuticals USA | 8 | $151 |
| Medtronic | 2 | $149 |
| Nevro Corp. | 1 | $146 |
| Amgen | 5 | $84 |
| Globus Medical | 1 | $33 |
| Smith+Nephew | 1 | $23 |
| Zimmer Biomet | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orbitum Staple System$6,493
- Orbitum Staple$3,534
- Omnia$146
- ClosureFast$133
How this compares
$10,626 in reported general payments places this provider in the 80th percentile of 239 foot & ankle surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 178 | $3,606 |
| Colchicine | 19 | $1,102 |
| Doxycycline Hyclate | 31 | $413 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 50 | $403 |
| Cephalexin | 85 | $366 |
| Clindamycin Hcl | 46 | $285 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $194 |
| Ibuprofen | 30 | $157 |
| Methylprednisolone | 31 | $124 |
| Ciprofloxacin Hcl | 25 | $102 |
| Azithromycin | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Peachtree City
- Scott RomanPeachtree City$118K
- Joseph GiovincoPeachtree City$18K
- William PearsonPeachtree City$12K
- Varsha AtuluruPeachtree City$11K
- Sidharth ReddyPeachtree City$7K
- Robert WeinsteinFayetteville$394K
- Jason BariteauAtlanta$199K
- Jeffrey FlashForest Park$114K
- Mickey StappThomson$110K
- David MurphyWaycross$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.